Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

NCT02979366 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukaemia (AML)
Myelodysplastic Syndrome (MDS)

Interventions

DRUG: S64315 once a week
DRUG: S64315 twice a week

Sponsor

Institut de Recherches Internationales Servier

Collaborators

[object Object]